Loss of active enhancers in CLL B cells. (A) Box plots showing the fold change of the indicated histone mark at the altered peaks in CLL B cells. The altered peaks were cut off at P < .01 and fold change of >2 between CLL and NBCs. (B) Representative snapshots showing the alteration of active histone marks in CLL B cells. (C) Venn diagrams showing the overlap of the downregulated or upregulated H3K4me1 and H3K27ac peaks in CLL B cells. (D) Representative metagene heat maps showing H3K4me1 and H3K27ac intensity of the indicated peaks in panel C. (E) Pathways associated with the genes putatively regulated by the downregulated enhancers (by GREAT) in CLL. (F) The expression of the downregulated enhance-associated genes (determined by GREAT). Gene expression was determined by RNA-seq. (G) The gene expression of leukocyte differentiation pathways genes. Gene expression was determined by RNA-seq. The gene cardiotrophin-like cytokine factor 1 (CLCF1) is marked by the red arrow. (H) A snapshot showing histone modification enrichment at gene locus CLCF1.